Cerevel Therapeutics

Last updated
Cerevel Therapeutics Holdings, Inc.
Company type Subsidiary
Industry Biopharmaceuticals
Founded2018;6 years ago (2018)
FateAcquired by AbbVie
Headquarters Cambridge, Massachusetts, U.S.
Number of employees
355 (2024)
Parent Abbvie
Website cerevel.com

Cerevel Therapeutics Holdings, Inc. is an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses. [1]

Contents

History

Cerevel was established in October 2018. [2] The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital. [3] [4]

In 2019, Cerevel appointed N. Anthony Coles as its chief executive officer. [5] In 2020, Coles led Cerevel's effort to raise $445 million for brain drugs, the third largest biotech public listing at that time (after Legend Biotech and Moderna). [6] In May 2023, Coles resigned from his position as CEO, yet retained his role as board chairman of Cerevel. [7]

In December 2023, American pharmaceutical company AbbVie announced its intention to acquire Cerevel for US$8.7 billion. [8] [9] [10] The acquisition was completed in August 2024 with Cerevel becoming a subsidiary of Abbvie. [11] [12]

Pipeline

Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more. [13]

Notable Cerevel drugs and treatments at varying stages of development include:

Approach to treatment

Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease. [19] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types. [1]

The company has stated its approach to neurotherapy development can be viewed as:

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Lundbeck</span> Danish pharmaceutical company

H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.

<span class="mw-page-title-main">Neurosteroid</span> Compounds that affect neuronal excitability through modulation of specific ionotropic receptors

Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">Acorda Therapeutics</span> American biotechnology company

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.

<span class="mw-page-title-main">AbbVie</span> American pharmaceutical company

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Gene therapy is being studied for some forms of epilepsy. It relies on viral or non-viral vectors to deliver DNA or RNA to target brain areas where seizures arise, in order to prevent the development of epilepsy or to reduce the frequency and/or severity of seizures. Gene therapy has delivered promising results in early stage clinical trials for other neurological disorders such as Parkinson's disease, raising the hope that it will become a treatment for intractable epilepsy.

Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Editas Medicine</span> Discovery-phase pharmaceutical company

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

CDKL5 deficiency disorder (CDD) is a rare genetic disorder caused by pathogenic variants in the gene CDKL5.

<span class="mw-page-title-main">Tavapadon</span> Chemical compound

Tavapadon is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is under development by Cerevel Therapeutics, which acquired tavapadon from Pfizer in 2018. It is taken by mouth.

Convection-enhanced delivery (CED) is method of drug delivery in which the drug is delivered into the brain using bulk flow rather than conventional diffusion. This is done by utilizing catheters inserted into the target region of the brain and utilizing pressure to deliver the therapeutic to a target region. CED has been used to delivery drugs to the central nervous system (CNS) for diseases such as cancer, epilepsy, and Parkinson's disease. CED has been used to deliver drugs to the CNS for its ability to bypass the blood–brain barrier (BBB) and target specific regions for targeted treatment, but current techniques using CED have failed to progress past clinical trials due to a variety of physical limitations associated with CED itself.

<span class="mw-page-title-main">Mevidalen</span> Chemical compound

Mevidalen is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease.

<span class="mw-page-title-main">Razpipadon</span> Chemical compound

Razpipadon is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken via oral administration.

<span class="mw-page-title-main">Icalcaprant</span> Chemical compound

Icalcaprant is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders. It is taken by mouth.

<span class="mw-page-title-main">Darigabat</span> Chemical compound

Darigabat is a GABAergic medication which is under development for the treatment of photosensitive epilepsy, focal onset seizures, panic disorder, and other anxiety disorders. It was also under development for the treatment of generalized anxiety disorder and chronic lower back pain, but development for these indications was discontinued. It is taken via oral administration.

<span class="mw-page-title-main">Emraclidine</span> Chemical compound

Emraclidine is an investigational antipsychotic for the treatment of both schizophrenia and Alzheimer's disease psychosis developed by Cerevel Therapeutics. As of February 2023, it is in phase II of clinical trial. Emraclidine is a positive allosteric modulator that selectively targets the muscarinic acetylcholine receptor M4 subtype. The M4 receptor subtype is expressed in the striatum of the brain, which plays a key role in regulating acetylcholine and dopamine levels. An imbalance of these neurotransmitters has been linked to psychotic symptoms in schizophrenia. Unlike other muscarinic receptors, M4 receptor subtypes are selectively expressed in the striatum and activation of these receptors has been shown to indirectly regulate dopamine levels without blocking D2/D3 receptors, which may lead to unwanted motor side effects seen in current antipsychotics.

N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.

References

  1. 1 2 3 4 5 "The Last Frontier of Medicine". Neurology live. 2023-04-21. Retrieved 2024-01-13.
  2. ↑ Logan, Tim (August 7, 2019). "Pfizer spinoff Cerevel moving into Cambridge Crossing". The Boston Globe. Retrieved 2024-01-13.
  3. ↑ "Bain Capital And Pfizer Create New CNS Company Cerevel Therapeutics". markets.businessinsider.com. 2024-01-12. Retrieved 2024-01-13.
  4. ↑ Brodwin, Erin. "Drug giant Pfizer isn't ready to abandon neuroscience — here's its $150-million 'star cluster' strategy for betting on promising brain drug startups". Business Insider. Retrieved 2024-01-13.
  5. ↑ Eides, Rachel. In the News: Cerevel Therapeutics Appoints Biotechnology Leader Tony Coles, M.D., as Chief Executive Officer. W20 pure. https://www.cerevel.com/newsroom/cerevel-therapeutics-appoints-biotechnology-leader-tony-coles-m-d-as-chief-executive-officer/
  6. ↑ Garde, Damian, and Matthew Herper. Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects. STAT. July 30, 2020. https://www.statnews.com/2020/07/30/coles-led-cerevel-therapeutics-to-raise-445-million-to-develop-brain-drugs-with-fewer-side-effects/
  7. ↑ Peebles, Angelica. Cerevel CEO Tony Coles Steps Down From Neuroscience Biotech: Bain Partner, former Translate Bio CEO will replace Coles, Coles to leave CEO post in June, to remain board chairman. Bloomberg. May 3, 2023. https://www.bloomberg.com/news/articles/2023-05-03/cerevel-ceo-tony-coles-steps-down-succeeded-by-ex-translate-bio-s-renaud
  8. ↑ Constantino, Annika Kim (2023-12-06). "AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion". CNBC. Retrieved 2024-01-13.
  9. ↑ Armstrong, Annalee (December 6, 2023). "AbbVie adds to neuroscience portfolio with $8.7B deal to acquire Cerevel". Fierce Biotech. Retrieved January 13, 2024.
  10. ↑ "AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline". AbbVie News Center. Retrieved 2024-01-13.
  11. ↑ "AbbVie Completes Acquisition of Cerevel Therapeutics" (Press release). AbbVie. August 1, 2024.
  12. ↑ Green, Hannah (July 26, 2024). "After FTC involvement, here's when AbbVie-Cerevel deal could close". Boston Business Journal.
  13. ↑ "EMPOWERing the Next Generation". Psychiatric Times. 2023-09-13. Retrieved 2024-01-13.
  14. ↑ "Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease – Cerevel Therapeutics". www.cerevel.com. 2020-01-14. Retrieved 2024-01-13.
  15. ↑ "Emraclidine – Cerevel Therapeutics". www.cerevel.com. 2020-01-04. Retrieved 2024-01-13.
  16. ↑ "Cerevel Therapeutics Announces Publication of Phase 2a Study Results in Neurology on Its Most Advanced Investigational Epilepsy Treatment – Cerevel Therapeutics". www.cerevel.com. 2019-04-09. Retrieved 2024-01-13.
  17. ↑ "CVL-871 – Cerevel Therapeutics". www.cerevel.com. 2020-01-02. Retrieved 2024-01-13.
  18. ↑ "CVL-354, a novel, brain penetrant and selective kappa opioid receptor antagonist – Cerevel Therapeutics". www.cerevel.com. 2022-12-01. Retrieved 2024-01-13.
  19. ↑ "EX-99". www.sec.gov. Retrieved 2024-01-13.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.